Caricamento...
Review article: systemic treatment of hepatocellular carcinoma
BACKGROUND: The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic therapy to show a survival benefit in patients with advanced hepatocellular carcinoma. Since then many drugs failed in the...
Salvato in:
| Pubblicato in: | Aliment Pharmacol Ther |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6120553/ https://ncbi.nlm.nih.gov/pubmed/30039640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14913 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|